Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

Bcl-2 Antagonist shown to be therapeutically effective in a mouse model of Chronic Lymphocytic Leukaemia

COPENHAGEN, 18 April 2007 - Santaris Pharma, the Danish biopharmaceutical company developing RNAi drugs, yesterday presented encouraging data at the American Association for Cancer Research Annual Meeting in Los Angeles, showing that SPC2996, the Company's RNA Antagonist of Bcl-2, is therapeutically active in a preclinical model of human Chronic Lymphocytic Leukaemia (CLL).

In collaboration with scientists at the University of Duisberg-Essen in Germany, Santaris researchers reported that white blood cells obtained from CLL patient peripheral blood can be transplanted into immunodeficient mice and reliable engraftment of human CLL cells achieved in the spleen, resulting in focal aggregates of B-lymphocytes carrying surface markers characteristic of CLL cancer cells.

SPC2996 was tested for anti-leukaemic activity over two weeks in this model starting two weeks after transplantation and compared for efficacy with multiple doses of fludarabine, a standard chemotherapy for CLL, as well as a negative control oligonucleotide drug similar to but of different sequence from SPC2996. Therapy with SPC2996 resulted in a 54% reduction (p=0.043) in the number of CLL cells which could be recovered from the spleens of the treated transplanted animals compared to animals not receiving therapy. Fludarabine was also effective in the model whereas the negative control drug was not.

This is the first time that primary CLL cells taken from patient blood have been successfully transplanted and shown long term splenic engraftment in an animal model. The model appears to be validated by the efficacy of the fludarabine in clearing engrafted human CLL cells. The demonstration that single agent therapy with SPC2996, a non-chemotoxic agent inhibiting Bcl-2 expression, also clears CLL cells from splenic engraft
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:7/29/2015)... 29, 2015  Medical Care Alert, a leading national ... announced availability of its new HOME & AWAY ELITE ... the neck or on the hip, the small two-ounce ... USA using the AT&T Wireless ... generation in mobile and automatic fall detection medical alert ...
(Date:7/29/2015)... YORK , July 29, 2015 /PRNewswire/ ... a new research report "Global Industry Insight: ... to 2020" with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... http://photos.prnewswire.com/prnh/20150727/756778 ) Microfluidic devices  ...
(Date:7/29/2015)... 2015 TAKE Solutions Ltd., a global business technology ... market for the Life Sciences sector, by setting up ... investment of 3 million USD . Intelent aims to ... (according to projections by McKinsey) by providing clients offerings in ... Noting the exponential ...
Breaking Medicine Technology:New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 2New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 3New Medical Care Alert Pendant Combines GPS, Cellular Voice, and Automatic Fall Detection 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 2TAKE Solutions Creates a New Subsidiary for Life Sciences Big Data in the US 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... - Asia-Pacific, Especially India and China, ... and Regulatory Pressures in Western Pharmaceutical ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... that it has entered into agreements with Quintiles ... Inc. (ICS) to support the anticipated launch of ... be approved by the Food and Drug Administration ...
Cached Medicine Technology:Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 2Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 3Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 4Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 5Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 6Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 7Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 8Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 9Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 10Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 2Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 3Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 4Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure 5
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - ... Atherosclerosis is a slow, progressive disease that may start in childhood. The report ... best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and ...
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, ... Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural pain reliever ... actively addressing Line of Duty Deaths (LODD) and the high rate of pain ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... anticipating testing regulations imposed by the FDA for nicotine laced liquid products. Their ... electronic cigarettes have raised considerably. E-Cigarettes are particularly troublesome to addiction professionals as ...
(Date:7/29/2015)... San Fernando Valley, CA (PRWEB) , ... July 29, 2015 , ... ... offering a special promotional price on Ultherapy. For a limited time only, patients can ... Ultherapy is an option for patients who prefer a non-invasive treatment and have ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty ... of looking good on the big day. Every bride wants to look and feel beautiful, ... , According to a recent study by the American Academy of ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... ImmuKnow(R) and anti-HLA antibody assays both contribute to ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed ... presented,today at the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... everolimus almost doubled survival time with pancreatic, kidney ... News) -- Patients diagnosed with pancreatic cancer -- ... doubled their overall survival when the cancer drug ... , Unfortunately, only about 15 percent of pancreatic ...
... drug prolonged progression-free survival, study finds , , SATURDAY, ... Avastin to chemotherapy lengthened progression-free survival in women ... Previous studies have found that adding Avastin (bevacizumab) ... with advanced breast cancer actually doubled progression-free survival. ...
... likely to have diminished ovarian reserve producing viable ... News) -- Chemotherapy may reduce fertility in breast ... researchers at Boston,s Dana-Farber Cancer Institute. , They ... chemotherapy following surgery were more likely than women ...
... young children has been linked to a significant number ... to recommend against their use for children less than ... efficacy, there has been little research on patterns of ... Now, a new study from the Emergency Medicine Network ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: